Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Boxed warning of HBV risk added to Rituxan, Arezerra
Multiple sclerosis: clinical presentation, diagnosis and treatment.
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
Rapid exacerbation of neuromyelitis optica after rituximab treatment.
Functional Characterization of DNA Methylation in the Oligodendrocyte Lineage.
Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability
SoCal Symposium on Glial-Neuronal Interactions in Health & Disease
Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.
Comparative miRNA-Based Fingerprinting Reveals Biological Differences in Human Olfactory Mucosa- and Bone-Marrow-Derived Mesenchymal Stromal Cells.
Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Gray matter SWI-filtered phase and atrophy are linked to disability in MS .
Gpr126 functions in Schwann cells to control differentiation and myelination via G-protein activation.
Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway.
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders.
Treatment satisfaction in multiple sclerosis.
Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide.
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
European Medicines Agency, Scientific Discussion of MabCampath (alemtuzumab)
Barcelona Pediatric MS and Related Disorders Update Meeting
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.
Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone.
Extensive bilateral lower extremity deep venous thrombosis in a patient on dimethyl fumarate.

Pages